Phreesia, Inc.
HealthcareNYSE:PHR · New York Stock Exchange
+$0.01 today
Vol 0.70M · Avg 2.02M
Management
Put operating results in leadership context
Review returns on capital, executive background, insider transactions, and growth quality to judge whether management is compounding value well.
Return Metrics
ROE, ROIC & ROA over time
ROE
0.7%
avg -19.7%
ROIC
0.3%
avg -27.2%
ROA
0.3%
avg -22.4%
Analysis
ROE is currently the strongest return metric at 0.7% versus its period average of -19.7%. 0 of 3 return metrics are above their quality threshold, which helps indicate how efficiently the company turns capital and assets into profit.
Management
Key executives, compensation & ownership
| Name | Title | Compensation | Tenure | Age | Shares Owned | Ownership % |
|---|---|---|---|---|---|---|
David Linetsky | President of Network Solutions | $610,465.00 | — | 45 | $12,134.00 | 0.02% |
Chaim Indig | Co-Founder, Chief Executive Officer & Director | $515,000.00 | — | 46 | $1.39M | 2.25% |
Balaji Gandhi | Chief Financial Officer | $400,000.00 | — | 51 | $156,931.00 | 0.25% |
Evan Roberts | Co-Founder & President of Provider Solutions | $400,000.00 | — | 46 | $842,501.00 | 1.36% |
Allison C. Hoffman | General Counsel & Secretary | $350,000.00 | — | 55 | $157,309.00 | 0.25% |
Jack Callahan | Chief Technology Officer | — | — | — | — | — |
Yvonne Hui | Senior VP & Chief Accounting Officer | — | — | 44 | $24,233.00 | 0.04% |
Nick Kemske | Chief Information Security Officer | — | — | — | — | — |
Amy Beth VanDuyn | Senior Vice President of Human Resources | — | — | 52 | $168,907.00 | 0.27% |
Briana Kearney | Vice President of Marketing | — | — | — | — | — |
Insider Trading
SEC Form 4 transactions — last 12 months
Buys
6
$28.77M
Sells
76
$10.39M
Net Sentiment
+$18.38M
Net buying
Most Active
Linetsky David
17 transactions
1–10 of 82
Analysis
Insiders reported 6 buys worth $28.77M and 76 sells worth $10.39M over the last 12 months. That adds up to net buying of $18.38M. Linetsky David was the most active insider with 17 transactions.
Growth Analysis
Historical CAGR & forward analyst estimates
| Metric | 10yr | 5yr | 3yr | Fwd Est. |
|---|---|---|---|---|
| EPS | N/A | N/A | N/A | N/A3 analysts |
| Revenue | N/A | N/A | +28.8% | +11.2% (9yr)1 analysts |
| Net Income | N/A | N/A | N/A | N/A1 analysts |
| EBIT | N/A | N/A | N/A | N/A1 analysts |
Analysis
Recent growth has been strongest in Revenue at +28.8% over three years. Forward estimates point to Revenue at +11.2% (9yr), giving you a quick check on whether expectations are accelerating or cooling.
Competitors
Peer companies in the same sector
Establishment Labs Holdings Inc.
NASDAQ:ESTA
$2.42B
NovoCure Limited
NASDAQ:NVCR
$2.06B
Neogen Corporation
NASDAQ:NEOG
$1.98B
Omnicell, Inc.
NASDAQ:OMCL
$1.72B
Teladoc Health, Inc.
NYSE:TDOC
$1.32B
BioLife Solutions, Inc.
NASDAQ:BLFS
$1.28B
Kestra Medical Technologies, Ltd.
NASDAQ:KMTS
$1.22B
Schrödinger, Inc.
NASDAQ:SDGR
$1.08B
Omada Health
NASDAQ:OMDA
$1.02B
GoodRx Holdings, Inc.
NASDAQ:GDRX
$918.57M
Who manages PHR?
Phreesia, Inc. (PHR) lists 10 active executives. The top listed executive is Balaji Gandhi, Chief Financial Officer.
Are PHR insiders buying or selling?
Recent insider activity shows net buying of $20.28M.
Explore More
Continue the stock analysis
Jump to another research area for this company.